TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24513242

Group type: EXPERIMENTAL
Intervention: Asymmetric tethering pattern
Number of subjects: 62

Group type: COMPARATOR
Intervention: Symmetric tethering pattern
Number of subjects: 62
Study: 23339378

Group type: COMPARATOR
Intervention: Socket allograft alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Socket allograft plus facial overlay xenograft
Number of subjects: 24
Study: 20005673

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10(-4)M
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%, 0.75%, 1%
Number of subjects: 0
Study: 18788033

Group type: EXPERIMENTAL
Intervention: Unipolar RF treatment
Number of subjects: 10
Study: 16172824

Group type: EXPERIMENTAL
Intervention: Computer-based swallowing safety training module
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (Control group)
Number of subjects: 0
Study: 12855342

Group type: EXPERIMENTAL
Intervention: Tramadol (275.5 mg/day average after dose adaptation)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 10475311

Group type: EXPERIMENTAL
Intervention: Epidural morphine for preemptive analgesia in limb surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural morphine for preemptive analgesia in mastectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural morphine for preemptive analgesia in gastrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural morphine for preemptive analgesia in hysterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural morphine for preemptive analgesia in herniorrhaphy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural morphine for preemptive analgesia in appendectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural morphine for preemptive analgesia in hemiorrhaphy
Number of subjects: 0
Study: 8595171

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 0.5 mg orally b.d.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 1.0 mg orally b.d.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 2.0 mg orally b.d.
Number of subjects: 80
Study: 2015175

Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen liquid in a gelatin capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen tablets (Nurofen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6799415

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 68

Group type: COMPARATOR
Intervention: Penicillin V, Amoxicillin, Ampicillin, Erythromycin estolate, Erythromycin ethylsuccinate, Trimethoprim-sulfamethoxazole, Cefaclor
Number of subjects: 68
Study: 31633369

Group type: EXPERIMENTAL
Intervention: Experiences that provide a correlation between space and time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiences that provide a correlation between space and number
Number of subjects: 0
Study: 29788075

Group type: EXPERIMENTAL
Intervention: PMT25341 (a mixture of synbiotics, omega-3/6 fatty acids and amino acids)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 29133706

Group type: COMPARATOR
Intervention: Hypothermia
Number of subjects: 107

Group type: COMPARATOR
Intervention: Progesterone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: COMPARATOR
Intervention: Progesterone + Hypothermia
Number of subjects: 107
Study: 25666004

Group type: EXPERIMENTAL
Intervention: 25 μg of intravaginal misoprostol
Number of subjects: 88

Group type: COMPARATOR
Intervention: 50 μg of intravaginal misoprostol
Number of subjects: 88
Study: 25091932

Group type: EXPERIMENTAL
Intervention: Sexual Health Model (SHM) - two sessions of 3 hours of group education
Number of subjects: 84

Group type: COMPARATOR
Intervention: PLISSIT model - total of 6 hours of one-on-one consultation at an interval of 1-2 weeks
Number of subjects: 84
Study: 22441644

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 19354344

Group type: EXPERIMENTAL
Intervention: Varenicline plus counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counselling alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study: 16780933

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 2817

Group type: COMPARATOR
Intervention: Oral anticoagulant therapy (OAT)
Number of subjects: 2817

Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 2817

Group type: COMPARATOR
Intervention: OAT
Number of subjects: 2817

Group type: EXPERIMENTAL
Intervention: LMWH and OAT
Number of subjects: 2817
Study: 15219299

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate plus albuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nebulized albuterol plus saline
Number of subjects: 0
Study: 11463516

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 618

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 618
Study: 9879606

Group type: EXPERIMENTAL
Intervention: 3 MU of lymphoblastoid IFN alpha 3 times a week for 12 months
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 3 MU of lymphoblastoid IFN alpha 3 times a week for 24 months
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 6 MU of lymphoblastoid IFN alpha 3 times a week for 12 months
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 6 MU of lymphoblastoid IFN alpha 3 times a week for 24 months
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Daily regimen of 3 MU for patients with unmodified AMT levels
Number of subjects: 504

Group type: COMPARATOR
Intervention: Comparison of 3 MU vs 6 MU
Number of subjects: 504

Group type: COMPARATOR
Intervention: 24-month treatment vs 12-month treatment
Number of subjects: 504

Group type: COMPARATOR
Intervention: Genotype analysis
Number of subjects: 504
Study: 7743871

Group type: EXPERIMENTAL
Intervention: Cross face transplantation of segmental latissimus dorsi muscle flap with super‐long neurovascular pedicle (one stage method)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cross face nerve graft and secondary free muscle transplantation by neurovascular anastomoses (two stage method)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Free muscle transplantation by microneurovascular anastomosis in paralyzed face
Number of subjects: 21

Group type: COMPARATOR
Intervention: One stage method (compared to sural nerve graft with small saphenous vein anastomosis)
Number of subjects: 21
Study: 2481532

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) concentrates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin (additional administration)
Number of subjects: 0
Study: 810198

Group type: EXPERIMENTAL
Intervention: Thyrotrophin-releasing hormone (TRH) 600 mug, given daily for four days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo, given daily for four days
Number of subjects: 20
Study: 31742629

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (n=57)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Immediate cord clamping (n=56)
Number of subjects: 113
Study: 28549430

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of reticulated hyaluronic acid (KARTILAGE® CROSS, 16 mg/ml, one single injection of 2.2 mL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of reticulated hyaluronic acid (KARTILAGE® CROSS)
Number of subjects: 81
Study: 25022226

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Medical therapy (MT)
Number of subjects: 13819

Group type: COMPARATOR
Intervention: Neurological events (NE) occurrence
Number of subjects: 13819
Study: 23707085

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.2 μg/kg/h for 30 minutes before the procedure, followed by 0.4 μg/kg/h for 6 hours after the procedure)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (volume‐matched normal saline solution)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 21718523

Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive-behavioral treatment for depression
Number of subjects: 12
Study: 18941066

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 47
Study: 15970035

Group type: EXPERIMENTAL
Intervention: Topical application of garlic paste for 14 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Clotrimazole solution
Number of subjects: 56
Study: 12520172

Group type: EXPERIMENTAL
Intervention: Sustained release tablets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular tablets
Number of subjects: 20
Study: 10754455

Group type: EXPERIMENTAL
Intervention: VML 295 at 200 mg twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: VML 295 at 200 mg once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8862229

Group type: COMPARATOR
Intervention: Carvedilol (C) (25 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alpha- and beta-adrenergic blockade
Number of subjects: 15
Study: 1636469

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment program
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Restraint score
Number of subjects: 459
Study: 6376404

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Thiamphenicol
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Cefazolin plus Thiamphenicol
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 750
Study: 30521781

Group type: EXPERIMENTAL
Intervention: Spinal mobilization with leg movement (SMWLM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise and electrotherapy
Number of subjects: 60
Study: 28744938

Group type: EXPERIMENTAL
Intervention: Integrative body-mind-spirit (I-BMS) intervention
Number of subjects: 185

Group type: COMPARATOR
Intervention: Waiting-list (Control)
Number of subjects: 185
Study: 26546385

Group type: EXPERIMENTAL
Intervention: Silver dressing
Number of subjects: 43
Study: 24925350

Group type: EXPERIMENTAL
Intervention: H. pylori treatment with amoxicillin‐omeprazole
Number of subjects: 2258
Study: 22924248

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 60
Study: 20333738

Group type: EXPERIMENTAL
Intervention: BoNT/A treatment after diode laser hair removal
Number of subjects: 9

Group type: COMPARATOR
Intervention: BoNT/A treatment without diode laser hair removal
Number of subjects: 9
Study: 18303744

Group type: EXPERIMENTAL
Intervention: Clean intermittent self‐catheterisation (CISC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Urethral dilatation with sounds
Number of subjects: 49
Study: 12682543

Group type: EXPERIMENTAL
Intervention: Diathermy hemorrhoidectomy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Stapled hemorrhoidectomy
Number of subjects: 31
Study: 10860190

Group type: EXPERIMENTAL
Intervention: ACE inhibition (Ramipril)
Number of subjects: 4937

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4937
Study: 9114632

Group type: EXPERIMENTAL
Intervention: Caregivers of patients with cancer-related pain
Number of subjects: 128

Group type: COMPARATOR
Intervention: Caregivers of pain-free patients
Number of subjects: 128
Study: 8470417

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1.2 mg sublingually)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nifedipine (10 mg capsule, chewed and swallowed)
Number of subjects: 40
Study: 2949080

Group type: EXPERIMENTAL
Intervention: Mode of presenting reinforcement (part of the sign-requested reinforcement)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Least-to-most prompting procedure
Number of subjects: 3

Group type: COMPARATOR
Intervention: Withdrawal of the least-to-most prompting procedure
Number of subjects: 3
Study: 29486502

Group type: EXPERIMENTAL
Intervention: Video Capsule Endoscopy (VCE)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Computed Tomography Colonography (CTC)
Number of subjects: 756
Study: 26700123

Group type: EXPERIMENTAL
Intervention: PRE-ACT
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Control (NCI text)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Both PRE-ACT and Control
Number of subjects: 1255
Study: 24468006

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Blood cardioplegia (Group 2)
Number of subjects: 100
Study: 22098442

Group type: EXPERIMENTAL
Intervention: Dried and crushed sea buckthorn berries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sea buckthorn CO₂ extraction residue (CO₂-sea buckthorn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sea buckthorn CO₂ and ethanol extraction residue (CO₂-EtOH-sea buckthorn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black currant CO₂ and ethanol extraction residue (CO₂-EtOH-black currant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (berry-depleted meals)
Number of subjects: 0
Study: 20117244

Group type: EXPERIMENTAL
Intervention: Continuous therapy with certolizumab pegol (400 mg every 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-interruption (placebo)
Number of subjects: 0
Study: 18825548

Group type: EXPERIMENTAL
Intervention: Methamphetamine use in the past 30 days
Number of subjects: 4605

Group type: EXPERIMENTAL
Intervention: Methamphetamine use in the past 12 months
Number of subjects: 4605
Study: 15912558

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 254

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 12734161

Group type: EXPERIMENTAL
Intervention: Belscope (BP)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Miller (MIL)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: McCoy (MC)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Macintosh (M)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Lee-Fiberview (LF)
Number of subjects: 500
Study: 10578479

Group type: EXPERIMENTAL
Intervention: Soy beverage containing 20 g of protein and 38 mg of total isoflavones
Number of subjects: 36
Study: 8934087

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at ten litres per minute through a specially modified non‐rebreathing mask
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supplemental oxygen at four litres per minute via nasal specular
Number of subjects: 100
Study: 1859515

Group type: EXPERIMENTAL
Intervention: Ticlopidine for 3 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (acetylsalicylic acid + dipyridamol)
Number of subjects: 15
Study: 6313596

Group type: EXPERIMENTAL
Intervention: Acyclovir (500 mg/m2/dose three times daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vidarabine (10 mg/kg/day for 5 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acyclovir (500 mg/m2/dose infused over one hour three times daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31200434

Group type: EXPERIMENTAL
Intervention: Group-based multicomponent physical exercise programme
Number of subjects: 0
Study: 27294374

Group type: EXPERIMENTAL
Intervention: Strength and sprint interval training (SIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strength and short interval training (INT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Strength-only training group (CON)
Number of subjects: 36
Study: 26099316

Group type: EXPERIMENTAL
Intervention: TAP blockade using ultrasound guidance
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control (no TAP blockade)
Number of subjects: 226
Study: 24552979

Group type: EXPERIMENTAL
Intervention: Monthly minodronate (50 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Weekly alendronate (35 mg)
Number of subjects: 38
Study: 22377800

Group type: EXPERIMENTAL
Intervention: Oral progesterone administration (25-50 mg at 16:00 and 20:00 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no progesterone)
Number of subjects: 18
Study: 19297462

Group type: COMPARATOR
Intervention: 0 microg vitamin D(3)/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 5 microg vitamin D(3)/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 10 microg vitamin D(3)/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 15 microg vitamin D(3)/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 8.6 microg/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 17.2 microg/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 24.7 microg/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 38.7 microg/d
Number of subjects: 225
Study: 17255295

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy before cytokine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted agents for advanced renal cell carcinoma
Number of subjects: 0
Study: 15356779

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily for 3 days
Number of subjects: 60
Study: 11377156

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both isoflurane and propofol anesthesia
Number of subjects: 24
Study: 9430327

Group type: EXPERIMENTAL
Intervention: Electrodermal testing
Number of subjects: 41
Study: 8276554

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 49

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 49

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 49

Group type: COMPARATOR
Intervention: Spinal and General anaesthesia
Number of subjects: 49
Study: 2959719

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 30
Study: 31468249

Group type: EXPERIMENTAL
Intervention: CBT (Cognitive-Behavioral Therapy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: COPE-CBT (Cognitive-Behavioral Therapy)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 39
Study: 29493373

Group type: EXPERIMENTAL
Intervention: MOVERS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NONMOVERS
Number of subjects: 0

Group type: COMPARATOR
Intervention: CONTROLS
Number of subjects: 0
Study: 27592487

Group type: EXPERIMENTAL
Intervention: Phloroglucinol
Number of subjects: 212

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 212
Study: 25447348

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) program; 18 visits of aerobic exercise at 60% to 80% of heart rate reserve
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 23373233

Group type: EXPERIMENTAL
Intervention: bi yan qing du ke li combined with nasal care
Number of subjects: 60

Group type: COMPARATOR
Intervention: bi yan qing du ke li
Number of subjects: 60
Study: 20644548

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg daily
Number of subjects: 46
Study: 18001721

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d orally; group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (1 tablet per d; group B)
Number of subjects: 110
Study: 15954870

Group type: EXPERIMENTAL
Intervention: 25 microg misoprostol intravaginally
Number of subjects: 77

Group type: COMPARATOR
Intervention: Gentle cervical assessment only
Number of subjects: 77
Study: 12801953

Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 8

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 8
Study: 12579104

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (24.34 mEq or 3 g in 100 mL saline solution administered over 2 hours preoperatively, perioperatively, and on postoperative days 0, 1, 2, and 3)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline solution (100 mL administered according to the same schedule as treatment group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 200
Study: 9523374

Group type: EXPERIMENTAL
Intervention: Low-dose oral baclofen administered for 14 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 7644831

Group type: EXPERIMENTAL
Intervention: audio‐auditory (auditory rhythms combined with an auditory model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: audio‐visual (auditory rhythms combined with a visual model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: auditory only (auditory rhythms with no model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: visual only (no auditory rhythms but exposure to a visual model)
Number of subjects: 0
Study: 2655690

Group type: EXPERIMENTAL
Intervention: Cyclosporin (CyA) with erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporin (CyA) without erythromycin
Number of subjects: 0
Study: 793842

Group type: EXPERIMENTAL
Intervention: Sodium valproate, 400 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Phenobarbital, 60 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium valproate and phenobarbital in combination
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31290104

Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 234